Latest Conference Articles

Lauren Banks, MD, PhD, discusses early lifileucel responses, safety findings, and next steps in the phase 2 SARATOGA trial for advanced soft tissue sarcoma.

Zev A. Wainberg, MD, MSc, reviews RASolute 302 findings on daraxonrasib's OS benefit across RAS genotypes in metastatic pancreatic cancer.

LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.

Bhavana Pothuri, MD, discusses TroFuse-005 at ESMO 2026, including TROP2 expression, treatment sequencing, and the future of endometrial cancer care.

Updated survival findings, perioperative treatment strategies, and circulating tumor DNA analyses highlight evolving approaches to genitourinary cancers.

Lauren Banks, MD, PhD, discusses TIL therapy feasibility and safety in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma.

Five ESMO 2026 abstracts report responses with 4 antibody-drug conjugates in ovarian cancer and a subcutaneous HER2-directed ADC plus PD-L1 inhibitor in cervical cancer.

Funda Meric-Bernstam, MD, discusses the outcomes of the FONTANA trial of an investigational folate receptor alpha–targeting antibody-drug conjugate in platinum-resistant ovarian cancer.

Late-breaking ESMO 2026 data show PFS gains with 3 antibody-drug conjugates, a 6-year OS benefit with adjuvant ribociclib, and no OS gain with pembrolizumab.

ADCs improved on chemotherapy-based regimens in PD-L1–negative and EGFR-mutated NSCLC, while chemotherapy plus pembrolizumab and pumitamig plus docetaxel showed activity in PD-L1–high and post-chemoimmunotherapy disease.

Bhavana Pothuri, MD, discusses phase 3 TroFuse-005 data from ESMO, where sac-TMT improved PFS and OS vs chemotherapy in endometrial cancer.

Domenica Lorusso, MD, PhD, discusses phase 3 findings on sacituzumab tirumotecan in advanced or recurrent endometrial cancer.

ESMO 2026 Presidential Symposium III: ADC and immunotherapy highlights from the the ARTEMIS-011, TroFuse-005, KEYNOTE-C93, and MOIO trials.

Brian M. Slomovitz, MD, discusses the outcomes of the KEYNOTE-C93 trial of pembrolizumab for endometrial cancer.

ESMO 2026 unveils GI cancer advances: targeted and immunotherapy regimens boost survival in pancreatic, colorectal, gastric, and HER2+ gastroesophageal disease.

Tamim Niazi, MDCM, discusses key findings from the phase 3 DASL-HiCaP study presented at the 2026 ESMO Congress.

Dr Jacob Sands discusses first-look OS and PFS data for tarlatamab plus durvalumab maintenance from the phase 3 DeLLphi-305 trial at ESMO 2026.

ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials.

Marcelo Vailati Negrao, MD, discusse safety outcomes with first-line olomorasib plus chemoimmunotherapy in LOXO-RAS-20001 and SUNRAY-01.

John Bridgewater, BA, MBBS, MRCP, PhD, discusses the potential impact of the phase 3 HARMONi-GI1 trial on treating advanced biliary tract cancer.

Jacob Sands, MD, discusses the top findings from the phase 3 DeLLphi-305 study evaluating tarlatamab and durvalumab as first-line maintenance in SCLC.

Danny Rischin, MD, on C-POST trial findings on prognostic value of ctDNA and DFS with adjuvant cemiplimab in high-risk CSCC.

Johanna S. Enke, MD, discusses safety findings from the Re-LuPSMA trial of lutetium Lu-177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.

Rahul Winayak, MD, explains new mRCC targets—GPR65, HPK1, ENPP3, CD70—that aim to overcome immunotherapy resistance.

Darren Feldman, MD, discusses phase 1 data showing ixotatug vedotin drives notable responses in heavily pretreated germ cell tumors, with manageable ADC safety and potential phase 2 plans.

Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.

Shannon Westin, MD, MPH, weighs in on B7-H4 ADCs in gynecologic cancers, focusing on testing, toxicity in maintenance use, and sequencing amid resistance, target shifts, and expanding options.

Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.

Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.

Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.